naphazoline
Trade name: visine
Approved
Jun 7, 1971
Naphazoline is a direct acting sympathomimetic adrenergic alpha-agonist used to induce systemic vasoconstriction, thereby decreasing nasal congestion and inducing constriction around the conjunctiva. The sympathomimetic action of Naphazoline constricts the smaller arterioles of the nasal passages, producing a decongesting effect. Naphazoline ophthalmic causes constriction of blood vessels in the eyes. It also decreases itching and irritation of the eyes. aphazoline constricts the vascular system of the conjunctiva. It is presumed that this effect is due to direct stimulation action of the drug upon the alpha adrenergic receptors in the arterioles of the conjunctiva resulting in decreased conjunctival congestion. Naphazoline belongs to the imidazoline class of sympathomimetics. Naphazoline is a direct acting sympathomimetic drug, which acts on alpha-adrenergic receptors in the arterioles of the nasal mucosa. This activates the adrenal system to yield systemic vasoconstrction. In producing vasoconstriction, the result is a decrease in blood flow in the nasal passages and consequently decreased nasal congestion. The vasoconstriction means that there is less pressure in the capillaries and less water can filter out, thus less discharge is made. Naphazoline is primarily indicated in conditions like Corneal vascularity, Hyperaemia, Itching, Nasal congestion, and can also be given in adjunctive therapy as an alternative drug of choice in Sinusitis. — NCATS
Clinical trial activity
9 trials · 9 clinical orgs · 11 marketing orgs
Earliest trial started May 1, 2008 (NCT00697541)
Timeline
1970s
- Jun 7, 1971
Earliest FDA Approval
- Jun 7, 1971
Novartis — Marketing Organization
- Mar 24, 1972
Allergan — Marketing Organization
- Mar 6, 1974
Alcon — Marketing Organization
- Aug 22, 1974
Akorn, Inc. — Marketing Organization
- Aug 22, 1974
Rising Pharmaceuticals — Marketing Organization
1980s
- Dec 1, 1981
Bausch & Lomb — Marketing Organization
1990s
- Apr 30, 1990
Novartis — NDA Secondary Org
- Jun 8, 1994
Bausch & Lomb — NDA Secondary Org
- Jun 8, 1994
Nestle — NDA Secondary Org
- Jan 31, 1996
Pfizer — First NDA Organization
- Jan 31, 1996
Johnson and Johnson — Marketing Organization
- Jan 31, 1996
Pfizer — NDA Organization
- Jan 31, 1996
Johnson and Johnson — NDA Secondary Org
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2008
Bausch & Lomb — Earliest Phase 3 Sponsor(trial)
2010s
- Sep 27, 2010
Altair Therapeutics — Marketing Organization
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
Combination products
opcon-a
with pheniramine
Also known as naphcon-a, visine
vasocon-a
with antazoline phosphate
Approval history
- approvedJun 7, 1971
Chemistry & pharmacology
SMILES
c1ccc2c(CC3=NCCN3)cccc2c1- Mol. weight
- 210.28 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Over the Counter
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL761 ↗
- WikipediaNaphazoline ↗
- NCATSH231GF11BV ↗
- ChEMBLCHEMBL1706 ↗
Also known as
- albalon
- albalon
- antistin-privine
- gppe nsl soln
- nafazair
- nafazair
- nafazolin
- nafazolin
- naphaz hcl
- naphazoline
- naphazoline
- naphazoline
- naphazoline
- naphazoline
- naphazoline
- naphazoline
- naphazoline
- naphazoline
- naphazoline hcl
- naphazoline hcl
- naphazoline hcl
- naphazoline hydrochloride
- naphazoline hydrochloride
- naphazoline hydrochloride
- naphazoline hydrochloride
- naphazoline hydrocloride
- naphazoline nitrate
- naphazoline nitrate
- naphazoline nitrate
- naphazoline nitrate
- naphazoline nitrate
- naphazoline nitrate
- naphcon
- naphcon
- naphcon forte
- naphcon forte
- naphthazoline
- naphthizine
- nephazoline
- opcon
- opcon
- rhinazine
- vasocon
- vasocon
- vasocon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05470868 | Phase 1 | Aug 1, 2022 | Laboratorios Sophia S.A de C.V. |
| NCT03324113 | Phase 1 | Oct 17, 2017 | Sanofi |
| NCT02601235 | Phase 3 | Mar 1, 2016 | EMS S/A, Faculdade de Medicina do ABC |
| NCT01533220 | Phase 3 | Jun 1, 2013 | EMS S/A |
| NCT01390961 | Phase 4 | Aug 1, 2011 | Allergan, Hom, Milton M., OD, FAAO |
| NCT01159015 | Phase 3 | Jul 1, 2010 | Bausch & Lomb |
| NCT00770133 | Phase 3 | Feb 1, 2010 | Bausch & Lomb |
| NCT00769886 | Phase 3 | Oct 1, 2008 | Bausch & Lomb |
| NCT00697541 | Phase 2 | May 1, 2008 | Galderma, KGL, Inc. |
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bausch & Lomb | For profit | 3 | 3 | 1 | 2008 |
| EMS S/A | For profit | 2 | 2 | 1 | 2013 |
| Allergan | For profit | 1 | 0 | 1 | 2011 |
| Faculdade de Medicina do ABC | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Galderma | For profit | 1 | 1 | 1 | 2008 |
| Hom, Milton M., OD, FAAO | Academic/Hospital | 1 | 1 | 1 | 2011 |
| KGL, Inc. | For profit | 1 | 0 | 1 | 2008 |
| Laboratorios Sophia S.A de C.V. | For profit | 1 | 1 | 1 | 2022 |
| Sanofi | For profit | 1 | 1 | 1 | 2017 |
Marketing (15)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Akorn, Inc. | For profit | MKTG | Aug 22, 1974 |
| Akorn, Inc. | For profit | SYN | Aug 22, 1974 |
| Alcon | For profit | MKTG | Mar 6, 1974 |
| Allergan | For profit | MKTG | Mar 24, 1972 |
| Altair Therapeutics | For profit | MKTG | Sep 27, 2010 |
| Bausch & Lomb | For profit | MKTG | Dec 1, 1981 |
| Bausch & Lomb | For profit | NDA2 | Jun 8, 1994 |
| Johnson and Johnson | For profit | MKTG | Jan 31, 1996 |
| Johnson and Johnson | For profit | NDA2 | Jan 31, 1996 |
| Nestle | For profit | NDA2 | Jun 8, 1994 |
| Novartis | For profit | MKTG | Jun 7, 1971 |
| Novartis | For profit | NDA2 | Apr 30, 1990 |
| Pfizer | For profit | NDA | Jan 31, 1996 |
| Pharmafair | For profit | MKTG | — |
| Rising Pharmaceuticals | For profit | MKTG | Aug 22, 1974 |